The maximum number of years of continuous use of Enasidenib

Enasidenib is a targeted drug developed for acute myeloid leukemia (AML) patients with IDH2 mutations. As an oral small molecule inhibitor, it can help restore the normal differentiation function of hematopoietic cells by inhibiting metabolic abnormalities caused by IDH2 mutations. In clinical application, one of the most common concerns of patients and their families is whether there is a limit on the "maximum number of years of continuous taking" of ensidipine. According to the currently disclosed overseas data, ensidipine is not strictly regulated for a maximum period of medication, but it is emphasized that ensidipine can be used continuously for a long time under the premise of good disease benefit and good tolerance.

The reason is that the treatment of acute myeloid leukemia is complex and long-term. Traditional chemotherapy often has a limited course of treatment, and the value of targeted drugs lies in its ability to control the abnormal metabolic processes of tumor cells for a long time and enable patients to maintain remission. Existing research results show that as long as patients respond well to ensidipine and the side effects are controllable, the drug can be continued as a"long-term maintenance treatment." Some patients can still maintain efficacy after receiving ensidipine treatment for more than one year or even several years, which shows that the safety and feasibility of long-term use of the drug are clinically recognized.

However, the long-term use of drugs also needs to be combined with the individual circumstances of the patient. Ensidipine may cause side effects including fluctuations in hematological indicators, increased bilirubin, loss of appetite, nausea, etc. Therefore, the attending physician will adjust the course of treatment based on the patient's tolerance. If some patients experience severe adverse reactions after their disease has stabilized, they may need to reduce the dose, take medication intermittently, or even consider discontinuing the medication. Overseas guidelines generally recommend that as long as the patient does not experience irreversible toxic reactions and the disease is controlled within the ideal range, ensidipine can be continued to be used, rather than setting a fixed number of years.

Reference materials:https://www.idhifa.com/